Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors — Meletios A Dimopoulos (2015) | RDL Network
David S. Siegel, Meletios A Dimopoulos, Heinz Ludwig, Thierry Façon, Hartmut Goldschmidt, Andrzej Jakubowiak, Jesús F. San Miguel, Mihaela Obreja, Julie Blædel, A. Keith Stewart
Thierry Façon, Rubén Niesvizky, María‐Victoria Mateos, David S. Siegel, Cara A. Rosenbaum, Sara Bringhen, Katja Weisel, P. Joy Ho, Heinz Ludwig, Shaji Kumar, Kenneth T. Wang, Mihaela Obreja, Zhao Yang, Zandra Klippel, Khalid Mezzi, Amanda Goldrick, Christina Tekle, Meletios A Dimopoulos
Katja Weisel, Meletios A Dimopoulos, Mark Cook, Karthik Ramasamy, Javier de la Rubia, Antonio Ardizzoia, Maria Theresa Krauth, Arnaud Jaccard, Niels W.C.J. van de Donk, Elisabeth Kueenburg, Antonia Di Micco, Barbara Rosettani, Margaret Atiba‐Davies, Pamela Bacon, Pieter Sonneveld
Meletios A Dimopoulos, K. Weisel, Kevin Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Philippe Moreau, A. Baños, Albert Oriol, L. Garderet, Michèle Cavo, V. L. Ivanova, Adrían Alegre, Joaquín Martínez‐López, Christopher Chen, Andrew Spencer, Stefan Knop, Nizar J. Bahlis, Christoph Renner, Xin Yu, Kevin Hong, Lars Sternås,
Discussion(0)
No comments yet. Be the first to comment.